Intracellular Delivery of Peptides and Proteins with an Engineered Membrane Translocation Domain

Antibodies and other protein therapeutics have revolutionized medicine, but their application is largely limited to extracellular targets. The lack of efficient intracellular delivery methods remains a major bottleneck. Here, we engineered a family of small (∼90 amino acids), metabolically stable membrane translocation domains (MTDs) by modifying the loop sequences of a human fibronectin type III (FN3) domain. The most potent variant, MTD4, is highly cell-permeable and can be recombinantly fused to the N- or C-terminus of any peptide or protein, serving as a versatile delivery vehicle. We demonstrate that MTD4 fusions efficiently deliver a wide variety of functional peptides and proteins into the cytosol and nucleus of eukaryotic cells, both in vitro and in vivo. Following systemic administration, an MTD4 fusion protein exhibited broad biodistribution and homogeneous tissue penetration in mice. Importantly, MTD4 is effective at low nanomolar (nM) concentrations, making it a promising platform for addressing a vast range of intracellular and previously ″undruggable″ targets.

Authors

Institutions

Publication Details

Journal
ACS Chemical Biology
Published
2026-06-30
DOI
https://doi.org/10.1021/acschembio.6c00383
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Intracellular Delivery of Peptides and Proteins with an Engineered Membrane Translocation Domain

Jenő Gyuris, Virginia L. King, Dehua Pei, Prabhat Bhat et al.
ACS Chemical Biology
RNA Interference and Gene Delivery
article

Intracellular Delivery of Peptides and Proteins with an Engineered Membrane Translocation Domain

Jenő Gyuris, Virginia L. King, Dehua Pei, Prabhat Bhat, Qi‐En Wang, Heba Salim, Brendan Harty, Jeremy L. Ritchey, Thomas Patel, J Zhao, Louis Tartaglia, Na Li
article en

Abstract

Antibodies and other protein therapeutics have revolutionized medicine, but their application is largely limited to extracellular targets. The lack of efficient intracellular delivery methods remains a major bottleneck. Here, we engineered a family of small (∼90 amino acids), metabolically stable membrane translocation domains (MTDs) by modifying the loop sequences of a human fibronectin type III (FN3) domain. The most potent variant, MTD4, is highly cell-permeable and can be recombinantly fused to the N- or C-terminus of any peptide or protein, serving as a versatile delivery vehicle. We demonstrate that MTD4 fusions efficiently deliver a wide variety of functional peptides and proteins into the cytosol and nucleus of eukaryotic cells, both in vitro and in vivo. Following systemic administration, an MTD4 fusion protein exhibited broad biodistribution and homogeneous tissue penetration in mice. Importantly, MTD4 is effective at low nanomolar (nM) concentrations, making it a promising platform for addressing a vast range of intracellular and previously ″undruggable″ targets.

ACS Chemical Biology
Lung Institute (US), Comprehensive Blood & Cancer Center (US), Proteostasis Therapeutics (United States) (US), U-M Rogel Cancer Center (US), The Ohio State University (US)
Openalex Percentile: Top 11%
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.